Cargando…

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer

A significant proportion of non-small cell lung cancer (NSCLC) patients experience accumulating chemotherapy-related adverse events, motivating the design of chemosensitizating strategies. The main cytotoxic damage induced by chemotherapeutic agents is DNA double-strand breaks (DSB). It is thus conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Manni, Chen, Siyuan, Wei, Yuquan, Wei, Xiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727896/ https://www.ncbi.nlm.nih.gov/pubmed/35024317 http://dx.doi.org/10.1016/j.apsb.2021.07.029

Ejemplares similares

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
por: Wise, Hannah C., et al.
Publicado: (2019)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
por: Carr, Michael I., et al.
Publicado: (2020)

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
por: Gordhandas, Sushmita B., et al.
Publicado: (2022)

Inhibition of NIPBL enhances the chemosensitivity of non-small-cell lung cancer cells via the DNA damage response and autophagy pathway
por: Zheng, Lei, et al.
Publicado: (2018)

Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma
por: Feng, Fei, et al.
Publicado: (2017)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
por: van Bussel, Mark T. J., et al.
Publicado: (2020)

Overexpression of Ulk2 inhibits proliferation and enhances chemosensitivity to cisplatin in non-small cell lung cancer
por: Cheng, Hong, et al.
Publicado: (2019)

Molecular mechanisms and clinical management of cancer bone metastasis
por: Wang, Manni, et al.
Publicado: (2020)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
por: Cheng, Yuan, et al.
Publicado: (2021)

An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
por: Chen, Fagui, et al.
Publicado: (2022)

Coronavirus in human diseases: Mechanisms and advances in clinical treatment
por: Lin, Panpan, et al.
Publicado: (2020)

Targeting TGF-β signal transduction for fibrosis and cancer therapy
por: Peng, Dandan, et al.
Publicado: (2022)

Mitochondrial DNA in the regulation of innate immune responses
por: Fang, Chunju, et al.
Publicado: (2015)

ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response
por: Shen, Hongchang, et al.
Publicado: (2017)

Cancer vaccines as promising immuno-therapeutics: platforms and current progress
por: Liu, Jian, et al.
Publicado: (2022)

Epigenetic regulation of macrophages: from homeostasis maintenance to host defense
por: Chen, Siyuan, et al.
Publicado: (2019)

DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
por: Xiao, Xiao, et al.
Publicado: (2018)

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
por: Hung, Man-Hsin, et al.
Publicado: (2015)

JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis
por: Chen, Siyuan, et al.
Publicado: (2023)

Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin
por: Xu, Xiaohui, et al.
Publicado: (2020)

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
por: Davidson, David, et al.
Publicado: (2013)

Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer
por: Linger, Rachel M.A., et al.
Publicado: (2012)

Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3
por: Li, Qingfang, et al.
Publicado: (2022)

Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition
por: Guo, Shenghu, et al.
Publicado: (2019)

Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells
por: Cao, Ziyang, et al.
Publicado: (2021)

Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer
por: XU, KE, et al.
Publicado: (2015)

Expression and prognostic impact of DNA-PK in human lung cancer
por: Tirilomi, Anna, et al.
Publicado: (2023)

CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression
por: Jin, Zihui, et al.
Publicado: (2023)

Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity through inhibition of autophagy
por: Wang, Zili, et al.
Publicado: (2017)

mRNA vaccine: a potential therapeutic strategy
por: Wang, Yang, et al.
Publicado: (2021)

A Mechanism for the Inhibition of DNA-PK-Mediated DNA Sensing by a Virus
por: Peters, Nicholas E., et al.
Publicado: (2013)

DNA-PK Is Targeted by Multiple Vaccinia Virus Proteins to Inhibit DNA Sensing
por: Scutts, Simon R., et al.
Publicado: (2018)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Opportunities and challenges in the nanoparticles for nucleic acid therapeutics: the first approval of an RNAi nanoparticle for treatment of a rare disease
por: Wei, Xiawei, et al.
Publicado: (2019)

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)
por: Glaysher, Sharon, et al.
Publicado: (2009)

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
por: Wei, Juan, et al.
Publicado: (2011)

miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein
por: Zhu, Xuchao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bpc9uss77g57hug12o775l5vaj